FBIO Fortress Biotech, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1429260 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.3%
TTM net income YoY2,411.2%
TTM EPS YoY2,016.7%
Revenue 3-yr CAGR-4.7%
Net income 3-yr CAGR—
Margins
Gross margin66.2%
Operating margin-42.5%
Net margin143.0%
FCF margin—
EBITDA margin-41.9%
Returns
ROE92.8%
ROA43.4%
ROIC (approx.)-227.3%
Asset turnover0.30x
Leverage & solvency
Liabilities / assets36.8%
Debt / equity0.00x
Current ratio2.93x
Interest coverage-3.17x
Cash quality & payout
Operating cash flow / net income1.26x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $63.26M | $57.67M | $84.51M | $75.74M | $68.79M |
| Cost of revenue | $20.92M | $20.88M | $22.89M | $30.77M | $32.08M |
| Gross profit | $42.34M | $36.80M | $61.62M | $44.97M | $36.71M |
| R&D expense | $11.90M | $56.63M | $101.75M | $134.88M | $128.87M |
| SG&A expense | $96.40M | $87.73M | $90.98M | $113.66M | $86.84M |
| Operating income | -$70.22M | -$110.38M | -$142.34M | -$203.56M | -$188.54M |
| Interest expense | $10.11M | $13.53M | $15.31M | $12.48M | $15.31M |
| Pretax income | -$33.53M | -$120.54M | -$153.63M | -$213.46M | -$164.35M |
| Income tax | -$620,000 | $312,000 | $521,000 | $449,000 | $473,000 |
| Net income | $6.82M | -$46.00M | -$60.64M | -$86.58M | -$64.70M |
| EBITDA | -$69.82M | -$109.34M | -$140.11M | -$200.46M | -$185.91M |
| EPS (basic) | -0.07 | -2.69 | -8.47 | -15.97 | -0.79 |
| EPS (diluted) | -0.07 | -2.69 | -8.47 | -15.97 | -0.79 |
| Weighted avg. shares (diluted) | 27.90M | 20.78M | 8.11M | 5.92M | 81.70M |
| Balance sheet | |||||
| Cash & equivalents | $79.38M | $58.81M | $83.36M | $180.95M | $307.96M |
| Receivables | $29.78M | $10.23M | $15.22M | $28.21M | $23.11M |
| Inventory | $9.62M | $14.43M | $10.21M | $14.16M | $9.86M |
| Current assets | $123.84M | $90.37M | $117.02M | $230.43M | $346.46M |
| PP&E, net | $2.52M | $3.26M | $6.50M | $13.02M | $15.07M |
| Intangibles | $27.61M | $31.86M | $20.29M | $27.20M | $12.55M |
| Total assets | $185.55M | $144.22M | $167.53M | $294.30M | $396.50M |
| Current liabilities | $49.74M | $71.40M | $84.91M | $127.72M | $101.04M |
| Long-term debt | $54.49M | $57.96M | $60.86M | $91.73M | $42.94M |
| Total debt | $54.49M | $57.96M | $60.86M | $91.73M | $42.94M |
| Total liabilities | $123.36M | $145.87M | $165.94M | $244.28M | $170.63M |
| Shareholders' equity | $49.87M | $22.74M | $22.54M | $41.72M | $108.67M |
| Net debt | -$24.89M | -$853,000 | -$22.51M | -$89.22M | -$265.03M |
| Shares outstanding | 31.36M | 27.91M | 15.09M | 7.37M | 101.44M |
| Cash flow statement | |||||
| Operating cash flow | -$65.78M | -$80.19M | -$128.22M | -$179.40M | -$116.54M |
| Capital expenditure | — | $0 | $63,000 | $2.71M | $4.57M |
| Free cash flow | — | -$80.19M | -$128.29M | -$182.12M | -$121.11M |
| Investing cash flow | $10.12M | -$15.00M | -$2.10M | -$22.93M | $40.51M |
| Financing cash flow | $77.44M | $70.64M | $32.74M | $75.32M | $148.99M |
| Depreciation & amortization | $403,000 | $1.04M | $2.23M | $3.11M | $2.63M |
| Stock-based compensation | $28.74M | $32.62M | $17.03M | $22.99M | $19.49M |
| Dividends paid | $664,000 | $694,000 | $736,000 | $749,000 | $749,000 |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.